1. Home
  2. VLYPO vs TGTX Comparison

VLYPO vs TGTX Comparison

Compare VLYPO & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B

VLYPO

Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B

HOLD

Current Price

$25.17

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$31.20

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VLYPO
TGTX
Founded
N/A
1993
Country
United States
United States
Employees
3732
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
5.5B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
VLYPO
TGTX
Price
$25.17
$31.20
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$54.75
AVG Volume (30 Days)
N/A
1.6M
Earning Date
N/A
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.78
Revenue
N/A
$531,898,000.00
Revenue This Year
N/A
$87.88
Revenue Next Year
N/A
$48.75
P/E Ratio
N/A
$11.16
Revenue Growth
N/A
100.88
52 Week Low
N/A
$25.28
52 Week High
N/A
$46.48

Technical Indicators

Market Signals
Indicator
VLYPO
TGTX
Relative Strength Index (RSI) 48.89 48.42
Support Level $24.96 $29.79
Resistance Level $25.59 $32.30
Average True Range (ATR) 0.17 1.09
MACD -0.03 0.03
Stochastic Oscillator 40.00 61.38

Price Performance

Historical Comparison
VLYPO
TGTX

About VLYPO Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B

Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: